(NASDAQ: PHVS) Pharvaris Nv's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.64%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.1%.
Pharvaris Nv's revenue in 2024 is $0.On average, 3 Wall Street analysts forecast PHVS's revenue for 2026 to be $556,158,695, with the lowest PHVS revenue forecast at $152,687,419, and the highest PHVS revenue forecast at $864,880,106. On average, 2 Wall Street analysts forecast PHVS's revenue for 2027 to be $7,461,760,962, with the lowest PHVS revenue forecast at $4,839,982,023, and the highest PHVS revenue forecast at $10,083,539,902.
In 2028, PHVS is forecast to generate $20,653,431,065 in revenue, with the lowest revenue forecast at $15,247,825,819 and the highest revenue forecast at $26,059,088,601.